Prezcobix and Sustiva contain active ingredients that do not go well together (a combination of darunavir and cobicistat, and efavirenz). Thus, they should not be co-administered. Consult a doctor to learn more about possible interactions and alternatives.
Prezcobix contains darunavir and cobicistat, antiretroviral agents suitable for the control of HIV infection . Darunavir is usually used in combination with other ARV drugs that can support its action and increase its effectiveness. This med is useful in the treatment of human immunodeficiency virus. While there is no cure for the infection, it effectively reduces the amount of virus in the blood by cutting the process of replication off.
Sustiva is an antiretroviral drug that contains efavirenz as its active ingredient. It is often administered in conjunction with other HIV medication to treat HIV infection . Sustiva belongs to a group of drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs). They function to control the virus by regulating its multiplicative activity.
Prezcobix is a double combination drug that contains darunavir and cobicistat. They act on different HIV enzymes to help control the infection.
Sustiva, on the other hand, which contains efavirenz as its active ingredient, helps regulate viral load, preventing the disease from progressing to AIDS.
Combining efavirenz with darunavir/cobicistat can be toxic to one’s health and can cause severe negative after-effects . Efavirenz is known to lower the concentrations of darunavir and cobicistat in the body. This can alter or terminate its curative action or effect and cause the virus to develop a resistance to darunavir.